# Results from the Survey of Antibiotic Resistance (SOAR) 2018–21 in Pakistan: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints

**Authors:** Didem Torumkuney, Summiya Nizamuddin, Ian Morrissey, Rendani Manenzhe, Anand Manoharan

PMC · DOI: 10.1093/jac/dkaf288 · Journal of Antimicrobial Chemotherapy · 2025-11-24

## TL;DR

This study analyzed antibiotic resistance in bacteria causing respiratory infections in Pakistan and found that many antibiotics remain effective despite concerns about misuse.

## Contribution

The study provides updated antibiotic susceptibility data using multiple breakpoints for S. pneumoniae and H. influenzae in Pakistan.

## Key findings

- Most isolates showed good susceptibility to amoxicillin, ceftriaxone, and fluoroquinolones.
- Cefdinir and cefaclor had lower activity, while tetracyclines and macrolides were poorly effective.
- EUCAST high-dose breakpoints showed similar or lower susceptibility for some antibiotics compared to CLSI.

## Abstract

To determine the antibiotic susceptibility of Streptococcus pneumoniae and Haemophilus influenzae isolates from community-acquired respiratory tract infections (CA-RTIs) collected in 2018–21 from Pakistan.

MICs were determined by CLSI broth microdilution; susceptibility data were interpreted using CLSI, EUCAST and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.

S. pneumoniae (n = 57) and H. influenzae (n = 67) were collected from the Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan. The proportion of penicillin-susceptible pneumococci was 28.1% by CLSI oral/EUCAST low-dose breakpoints; 98.3%/98.2% were susceptible by EUCAST high-dose/CLSI intravenous breakpoints. Good activity (≥93.0%) was observed using CLSI or PK/PD breakpoints for amoxicillin, amoxicillin/clavulanic acid, cefotaxime, cefpodoxime, ceftriaxone, cefuroxime, levofloxacin and moxifloxacin. Cefdinir and cefaclor were less active (75.4% and 57.9%, respectively, by CLSI and 61.4% and 19.3%, respectively, by PK/PD). Tetracyclines, macrolides and trimethoprim/sulfamethoxazole were poorly active (5.3%–36.8%). EUCAST high-dose breakpoints indicated similar activity, although susceptibility to cefaclor (0%), cefpodoxime (70.2%) and cefuroxime (68.4%) was lower than by CLSI. Most H. influenzae isolates were β-lactamase negative (95.5%). Generally, antibiotic susceptibility was >83.6% by CLSI for all antibiotics except trimethoprim/sulfamethoxazole (13.4%). Susceptibility by EUCAST was similar, except for cefuroxime (oral), with 0% susceptible isolates versus 95.5% by CLSI and 67.2% by PK/PD, fluoroquinolones and macrolides (no EUCAST breakpoint). Macrolide susceptibility by PK/PD breakpoints was low.

Although antimicrobial resistance was observed, many therapeutic options remain to treat S. pneumoniae and H. influenzae from CA-RTI in Pakistan despite concerns about high levels of inappropriate antibiotic use. Continued surveillance of antibiotic susceptibility is important for guiding empiric therapy of CA-RTIs.

## Linked entities

- **Chemicals:** penicillin (PubChem CID 2349), amoxicillin (PubChem CID 33613), amoxicillin/clavulanic acid (PubChem CID 6435924), cefotaxime (PubChem CID 5742673), cefpodoxime (PubChem CID 6335986), ceftriaxone (PubChem CID 5479530), cefuroxime (PubChem CID 5479529), levofloxacin (PubChem CID 149096), moxifloxacin (PubChem CID 152946), cefaclor (PubChem CID 51039), trimethoprim/sulfamethoxazole (PubChem CID 358641)
- **Species:** Streptococcus pneumoniae (taxon 1313), Haemophilus influenzae (taxon 727)

## Full-text entities

- **Diseases:** respiratory tract infections (MESH:D012141), Cancer (MESH:D009369)
- **Chemicals:** cefaclor (MESH:D002433), fluoroquinolones (MESH:D024841), cefuroxime (MESH:D002444), Tetracyclines (MESH:D013754), CA (MESH:D002118), Macrolide (MESH:D018942), amoxicillin (MESH:D000658), cefpodoxime (MESH:C053268), Cefdinir (MESH:D000077525), ceftriaxone (MESH:D002443), trimethoprim/sulfamethoxazole (MESH:D015662), penicillin (MESH:D010406), moxifloxacin (MESH:D000077266), amoxicillin/clavulanic acid (MESH:D019980), levofloxacin (MESH:D064704), cefotaxime (MESH:D002439)
- **Species:** Haemophilus influenzae (species) [taxon 727], Streptococcus pneumoniae (species) [taxon 1313]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12641124/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12641124/full.md

## References

21 references — full list in the complete paper: https://tomesphere.com/paper/PMC12641124/full.md

---
Source: https://tomesphere.com/paper/PMC12641124